论文部分内容阅读
目的:观察保守治疗良性前列腺增生症患者的用药情况和临床价值。方法:调查我院268例良性前列腺增生患者2009年本类药物的用药信息,以限定日剂量(DDD)、用药频度(DDDs)和药物利用指数(DUI)等指标进行分析,并记录治疗前后患者的国际前列腺症状评分(IPSS)、最大尿流率(MFR)、平均尿流率(AFR)、残余尿量(RU)、前列腺体积等变化。结果:高选择性α肾上腺素受体阻断剂、5-α还原酶抑制剂、天然植物类等3类药物在本组病例中使用最为广泛,特拉唑嗪用药频度最高;经过治疗,患者的IPSS评分及残余尿量明显下降(P<0.01),而MFR与AFR均明显增加,差异有统计学意义(P<0.01),前列腺体积治疗前后比较差异无统计学意义(P>0.05)。结论:良性前列腺增生症患者临床使用本类药物以α肾上腺素受体阻断剂为主,天然植物类药使用频率较高,药物利用指数评价基本合理,并对症状的改善、提高患者的生活质量等方面具有良好的临床实用价值。
Objective: To observe the conservative treatment of benign prostatic hyperplasia patients with medication and clinical value. Methods: A total of 268 patients with benign prostatic hyperplasia (BPH) in our hospital were investigated for drug use in 2009 and DDD, DDDs and DUI were used to analyze the data. Before and after treatment Patient’s International Prostate Symptom Score (IPSS), maximum flow rate (MFR), average flow rate (AFR), residual urine volume (RU), prostate volume and other changes. Results: Three kinds of drugs, such as highly selective α-adrenergic receptor blockers, 5-α reductase inhibitors and natural plants, were the most widely used in this group of patients and the highest frequency of terazosin was used. After treatment, The patients’ IPSS score and residual urine volume decreased significantly (P <0.01), while the MFR and AFR increased significantly (P <0.01), there was no significant difference between before and after prostate volume treatment (P> 0.05) . Conclusion: Benign prostatic hyperplasia patients clinical use of these drugs to alpha adrenergic receptor blockers, natural plant drugs to use a higher frequency of drug utilization index evaluation of the basic and reasonable, and the improvement of symptoms and improve patient’s life Quality and so has a good clinical value.